Latest Regulatory News

Manuka Resources’ Taranaki VTM Project has cleared a key regulatory hurdle, moving forward in New Zealand’s Fast-track Approvals Process with promising economic and environmental prospects.

Catalyst Metals has received the final environmental approval to begin mining at its Trident Gold Project, marking a key step in its plan to double production at the Plutonic Gold Belt.

Tasman Resources Ltd has announced a renounceable pro-rata rights issue aiming to raise up to $3.68 million to finance exploration drilling at its Parkinson Dam project and reduce shareholder debt. Major shareholders plan to fully subscribe, using loan repayments to offset their entitlements.

GPT Group and QuadReal Property Group have partnered to create a $1 billion logistics joint venture focused on Australia's east coast, aiming to expand their footprint in stabilised and core plus logistics assets.

Mayne Pharma Group has proposed a $7.40 per share acquisition by Cosette Pharmaceuticals, with unanimous board support and a fair and reasonable opinion from an independent expert. Shareholders will vote on the scheme on June 18, 2025.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Sigma Healthcare has released its standalone annual and sustainability reports for the year ending January 2025, marking the final disclosures before its merger with Chemist Warehouse Group in February 2025.

Embark Early Education announces a fully franked interim dividend and the conditional acquisition of two Queensland childcare centres, boosting its portfolio to 40 centres.

Aspen Group has launched a $74 million equity raising to reduce debt and capitalize on growth opportunities in affordable housing, maintaining its FY25 earnings guidance.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Southern Cross Gold has successfully closed the second tranche of its C$143 million private placement, securing nearly C$30 million to fund critical milestones at its Sunday Creek Gold-Antimony Project in Australia.

Peak Rare Earths is poised for acquisition by Shenghe Resources in a deal valuing the company at A$150.5 million, supported by a A$7.5 million entitlement offer to fund ongoing development and transaction costs.